ONCOLOGY Staff

HER-directed treatment approaches in the tumor-agnostic field were the highlight of the discussion for a panel of experts who convened at WCLC 2024.

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.

A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.

Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.

The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.

Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.

Experts spoke about the best practices for mitigating adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.

Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.

Findings from the phase 3 MARIPOSA-2 trial were the subject of a recent discussion of ambivantamab plus chemotherapy with or without lazertinib in EGFR-mutated NSCLC.

Minimal residual disease as an end point in multiple myeloma has been widely discussed and was even a topic of a recent ODAC meeting.

Experts in multiple myeloma sat down to discuss the use of bispecific antibodies and their impact in the space.

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.

The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.

The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.

A panel of experts in multiple myeloma discussed strategies for sequencing novel bispecific antibodies and CAR T-cell therapies for patients with relapsed/refractory disease.

Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.

Michael Wang, MD, spoke about the recent liso-cel approval in mantle cell lymphoma and the TRANSCEND trial.

Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.

During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.

A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.

Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care.

Hans Hammers, MD, and his team discuss the most pertinent treatment options for patients with renal cell carcinoma.

Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition.

Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.

Jun Gong, MD, and Daneng Li, MD, discussed the most impactful trials coming from 2024 ASCO GI.